Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Bogart

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|October 9, 2021
Treatment Patterns and Disease Burden Associated with Multiple-Inhaler Triple-Therapy Use in AsthmaJohn Oppenheimer, Michael Bogart, Lindsay G S Bengtson, et al.
Allergy and Asthma Proceedings|September 2, 2020
Impact of mepolizumab on exacerbations in severe asthma: Results from a U.S. insurance claims data baseHector Ortega, Beth Hahn, Michael Bogart, et al.
The Journal of Allergy and Clinical Immunology. Global|March 2, 2026
Burden of chronic oral corticosteroids among adults with asthma in the United StatesBrian Modena, Michael Bogart, Carlyne Averell, et al.
Journal of Comparative Effectiveness Research|August 18, 2017
Real-world comparison of treatment patterns and effectiveness of albiglutide and liraglutideErin K Buysman, Mirko V Sikirica, Sarah W Thayer, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 26, 2021
Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbiditiesThomas Casale, Nestor A Molfino, Jared Silver, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 14, 2021
A real-world study of inhaled corticosteroid use in patients with severe eosinophilic asthma treated with mepolizumabJonathan Corren, Jared Silver, Nestor A Molfino, et al.
Journal of Asthma and Allergy|February 27, 2020
Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and CostsJean-Pierre Llanos, Hector Ortega, Michael Bogart, et al.
International Journal of Chronic Obstructive Pulmonary Disease|January 16, 2024
Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United StatesMichael Bogart, Lindsay G S Bengtson, Mary G Johnson, et al.
Journal of Asthma and Allergy|December 7, 2023
Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the USMichael Bogart, Guillaume Germain, François Laliberté, et al.
Respiratory Medicine|April 16, 2022
Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world studyDavid Mannino, Michael Bogart, Benjamin Wu, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
The Journal of Allergy and Clinical Immunology. in Practice|October 9, 2021
Treatment Patterns and Disease Burden Associated with Multiple-Inhaler Triple-Therapy Use in AsthmaJohn Oppenheimer, Michael Bogart, Lindsay G S Bengtson, et al.
Allergy and Asthma Proceedings|September 2, 2020
Impact of mepolizumab on exacerbations in severe asthma: Results from a U.S. insurance claims data baseHector Ortega, Beth Hahn, Michael Bogart, et al.
The Journal of Allergy and Clinical Immunology. Global|March 2, 2026
Burden of chronic oral corticosteroids among adults with asthma in the United StatesBrian Modena, Michael Bogart, Carlyne Averell, et al.
Journal of Comparative Effectiveness Research|August 18, 2017
Real-world comparison of treatment patterns and effectiveness of albiglutide and liraglutideErin K Buysman, Mirko V Sikirica, Sarah W Thayer, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 26, 2021
Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbiditiesThomas Casale, Nestor A Molfino, Jared Silver, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 14, 2021
A real-world study of inhaled corticosteroid use in patients with severe eosinophilic asthma treated with mepolizumabJonathan Corren, Jared Silver, Nestor A Molfino, et al.
Journal of Asthma and Allergy|February 27, 2020
Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and CostsJean-Pierre Llanos, Hector Ortega, Michael Bogart, et al.
International Journal of Chronic Obstructive Pulmonary Disease|January 16, 2024
Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United StatesMichael Bogart, Lindsay G S Bengtson, Mary G Johnson, et al.
Journal of Asthma and Allergy|December 7, 2023
Real-World Study of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol on Asthma Control in the USMichael Bogart, Guillaume Germain, François Laliberté, et al.
Respiratory Medicine|April 16, 2022
Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world studyDavid Mannino, Michael Bogart, Benjamin Wu, et al.
Pageof 4